Advocacy intelligence hub — real-time data for patient organizations
Rondo Therapeutics — PHASE1
National Cancer Institute (NCI) — PHASE2
National Cancer Institute (NCI) — PHASE2
BeiGene — PHASE1
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — PHASE2
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Invitae Corporation
IDEAYA Biosciences — PHASE1
AstraZeneca — PHASE1, PHASE2
BicycleTx Limited — PHASE1, PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Valstar
Endo
Valstar
(Valrubicin)Orphan drugAnthra Pharmaceuticals, Inc.
12.1 Mechanism of Action Valrubicin is an anthracycline that affects a variety of interrelated biological functions, most of which involve nucleic aci...
IMFINZI
(durvalumab)Orphan drugstandardAstraZeneca Pharmaceuticals LP
Programmed Death Ligand-1 Blocker [EPC]
12.1 Mechanism of Action Expression of programmed cell death ligand-1 (PD-L1) can be induced by inflammatory signals (e.g., IFN-gamma) and can be expr...
TEPADINA
(THIOTEPA)Orphan drugstandardAmneal Pharmaceuticals LLC
Andrea B Apolo
National Cancer Institute LAO
📍 Birmingham, Alabama
Andrea B Apolo, M.D., MD
National Cancer Institute (NCI)
📍 BETHESDA, MD
David Hong, MD
M.D. Anderson Cancer Center
Vincent Chung, MD
City of Hope Medical Center
📍 DUARTE, CA
Samuel Funt, MD, M.D
Memorial Sloan Kettering Cancer Center
📍 NEW YORK, NY
Jonathan W Riess, MD, MSc, M.D., M.S
Division of Hematology/Oncology, UC Davis Comprehensive Cancer Center
📍 SACRAMENTO, CA